Stay updated with breaking news from Michael Klichinsky. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study is designed to evaluate the potential for a synergistic effect of CAR-M therapy in combination with KEYTRUDA® PHILADELPHIA, June 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) (
Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.
CARM | Complete Carisma Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Carisma Therapeutics (NASDAQ:CARM – Get Rating) is one of 997 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Carisma Therapeutics to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends. Earnings & Valuation This […]
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...